Strs Ohio Increases Holdings in STERIS plc $STE

Strs Ohio grew its holdings in STERIS plc (NYSE:STE) by 62.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,552 shares of the medical equipment provider’s stock after acquiring an additional 25,204 shares during the period. Strs Ohio’s holdings in STERIS were worth $16,619,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in STE. Steigerwald Gordon & Koch Inc. purchased a new position in shares of STERIS in the third quarter valued at about $25,000. Board of the Pension Protection Fund purchased a new stake in shares of STERIS in the fourth quarter worth about $25,000. Harbor Investment Advisory LLC lifted its position in shares of STERIS by 115.4% in the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 60 shares in the last quarter. Activest Wealth Management increased its stake in STERIS by 423.8% during the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 89 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its stake in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 104 shares during the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

STERIS Stock Up 0.2%

Shares of NYSE STE opened at $214.78 on Monday. The stock has a 50 day moving average price of $226.36 and a 200 day moving average price of $244.80. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The firm has a market capitalization of $21.06 billion, a price-to-earnings ratio of 29.96 and a beta of 0.95. STERIS plc has a 52-week low of $209.98 and a 52-week high of $269.44.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The business’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Sell-side analysts expect that STERIS plc will post 10.22 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on STE shares. Weiss Ratings cut STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, April 16th. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $275.20.

Insiders Place Their Bets

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the completion of the sale, the director owned 705 shares in the company, valued at $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.07% of the stock is currently owned by corporate insiders.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.